Sensifree is focused on helping physicians in hospitals to do their work better. In developing our products, we work closely with clinicians on the best ways to provide them with the information they need, while simplifying their work processes and reducing workload.
Our innovative technology facilitates easy to use solutions, supporting clinician’s decision making towards a better patient care.
We, like our customers, value affordable, easy to use solutions. We made these standard design objectives in all of our products.
Our first product implements Sensifree’s patent pending, novel technology for continuous, non-invasive blood pressure (cNIBP) monitoring. This product uses the ubiquitous, low-cost fingertip SpO2 sensor to provide functionality that otherwise requires either invasive or very expensive solutions. Our aim is to extend cNIBP to larger group of patients and make it the new standard of care in hospital BP monitoring.
The merits of continuous blood pressure (BP) monitoring have long been established, with arterial lines commonly accepted as the gold standard. However, the invasive nature of arterial line, the relative procedural complexity and associated complications, limit its use to cases where the risk is justified.
Arterial lines are mostly used with acute patients in intensive care units (ICU), high dependency units and in anaesthetized patients undergoing surgical procedures. For less acute patients, the associated risk, complexity, and management of cannulated patients often outweigh the benefits of invasive continuous BP monitoring.
In most cases, BP is still monitored using a technology that hasn’t changed much for more than a century – the inflatable BP cuff. Even when used in automatic monitors, it provides only intermittent readings and frequent cuff measurements are not well tolerated by patients.
Numerous studies have shown the shortcomings of intermittent BP readings, both in acute care settings and in the general wards, resulting in missing out events of high or low BP. These events, going unnoticed by medical personnel, manifest themselves in serious complications and even death.
A low risk, low-cost, easy to use method for continuous, non-invasive BP (cNIBP) monitoring would therefore have a great value in the treatment of hospitalized patients, going through the various stages of their admission.
Our products are well tolerated by patients and affordable to the healthcare provider. We are initially targeting in-hospital applications in general & surgical wards, and critical care units. Our roadmap includes the release of additional vital signs parameters to enable broader view on patients’ condition. We further plan to expand beyond the hospital walls to offer remote monitoring of patients discharged from the hospital and patients with certain chronic conditions, such as hypertension, end stage renal disease and preeclampsia.
Our proprietary, patent pending technology platform comprises of two main elements:
1. Unique technology, based on the use of standard optical (PPG) sensors
2. Advanced algorithmic layer to calculate and track blood pressure
Our sensor features red and infra-red wavelengths that track blood volume inside the pulsating blood vessel and then constructing a unique signal, originating at the index finger. The result is a continuous waveform that is proportional to the arterial pressure wave.
We then apply our proprietary algorithms, based on biomechanical modeling of the cardiovascular system to extract and track systolic and diastolic blood pressures, as well as mean arterial pressure (MAP).
We analyzed data from more than 250 patients with over 1.6 million data points with reference to arterial line, the gold standard.
The comparison demonstrated that our accuracy results are within the FDA requirements for blood pressure monitors, according to the ISO81060-2 standard.
Cupertino, Calif. (July 10, 2018) – Sensifree, a medical device company developing advanced RF-based hemodynamic monitoring solutions, announces that it has been chosen from thousands of entrants as a winner of the Red Herring Top 100 North America 2018 award. The award recognizes Sensifree as among this year’s most exciting and innovative private technology companies in the North American business region.
“We are honored to be a Red Herring Top 100 winner, which is an important acknowledgment of our innovative solution to continuous blood pressure monitoring without the need for an invasive arterial line,” said Eran Agmon, Sensifree’s co-founder and CEO. “We are well positioned to accelerate development of our first product, a blood pressure monitoring solution for critical care settings, and advance this product toward commercialization.”
Companies considered for the 2018 Red Herring Top North American award were judged by industry experts, insiders and journalists on a wide variety of criteria including financial performance, innovation, business strategy and market penetration.
Red Herring’s editors have been evaluating the world’s startups and tech companies for over two decades. It gives them the ability to see through the industry’s hype, to pick firms that will continue on a trajectory to success. Brands such as Alibaba, Google, Kakao, Skype, Spotify, Twitter and YouTube have all been singled out in Red Herring’s storied history.
“2018’s crop of Top 100 winners has been among our most intriguing yet,” said Red Herring chairman Alex Vieux. “North America has led the way in tech for so many years, and to see such unique, pioneering entrepreneurs and companies here in California, which is in many ways the heartland of the industry, has been a thrilling experience.
“What has excited me most is to see so many people forging niches in high-tech and cutting-edge sectors,” added Vieux. “Some of the technical wizardry and first-rate business models on show here at the conference has been fantastic to learn about. We believe Sensifree embodies the drive, skill and passion on which tech thrives. Sensifree should be proud of its achievement: the competition was incredibly strong.”
Cupertino, Calif. (June 14, 2018) – Sensifree, a medical device company developing advanced RF-based hemodynamic monitoring solutions, announced today it has been selected as a finalist for Red Herring’s Top 100 North America award, a prestigious list honoring the year’s most promising private technology ventures from the North American business region.
The Red Herring editorial team selected the most innovative companies from a pool of hundreds from across North America. The nominees are evaluated on 20 main quantitative and qualitative criterion, which include disruptive impact, market footprint, proof of concept, financial performance, technology innovation, social value, quality of management, execution of strategy, and integration into their respective industries.
This unique assessment of potential is complemented by a review of the track record and standing of a company, which allows Red Herring to see past the “buzz” and make the list a valuable instrument for discovering and advocating the greatest business opportunities in the industry.
“This year was rewarding, beyond all expectations” said Alex Vieux, publisher and CEO of Red Herring. “There are many great companies generating really innovative and disruptive products in North America. We had a very difficult time narrowing the pool and selecting the finalists. Sensifree shows great promise and therefore deserves to be among the finalists. Now we’re faced with the difficult task of selecting the Top 100 winners of Red Herring North America. We know that the 2018 crop will grow into some amazing companies that are sure to make an impact.”
Finalists for the 2018 edition of the Red Herring 100 North America award are selected based upon their technological innovation, management strength, market size, investor record, customer acquisition, and financial health. During the months leading up to the announcement, Red Herring reviewed over 1200 companies in the telecommunications, security, cloud, software, hardware, biotech, mobile and other industries that completed their submissions to qualify for the award.
Sensifree’s CEO, Eran Agmon, will present at the Red Herring North America Forum in Marina Del Rey, June 18-20, 2018. The Top 100 winners will be announced at a special awards ceremony on the evening of June 20 at the event.
Cupertino, Calif. – (BUSINESS WIRE) – Sensifree, a medical device company developing advanced RF-based hemodynamic monitoring solutions, announces results of a clinical study showing excellent concordance between the signal morphology of its RF based sensor and invasive arterial line, the standard of care for continuous blood pressure monitoring. Clinical data from the study further validate blood pressure extraction and tracking algorithms. Preliminary results demonstrate accurate tracking of systolic and diastolic pressure values.
Neuchâtel (CH), Cupertino, CA (US), and Petach-Tikva (IL); January 23, 2017—Sensifree and CSEM join forces to create a disruptive technology for monitoring blood pressure without using a cuff. Combining CSEM’s expertise in the field of blood pressure monitoring and Sensifree’s novel, RF-based approach will pave the way for the production of a new tool for the highly attractive health wearables market.
Sensifree Ltd. (Cupertino, Calif.) was founded in 2012 and claims to have developed a contact free, electromagnetic sensor that accurately collect a range of continuous biometric data without the need to touch the human body. The Sensifree technology uses RF signal to sense movement in the radial artery wall to track heart rate, and in the future blood pressure. Having taken the pulse digital signal processing is used to extract more information.
Cupertino, CA and Petach-Tikva, Israel, May 24, 2016 — Sensifree, the pioneer in low power, contact free, electromagnetic sensors that accurately collect a range of continuous biometric data without the need to touch the human body, today announced it has completed a $5.0 million Series A round of financing. TransLink Capital led the investment round with participation from existing and new investors, including UMC Capital, a subsidiary of United Microelectronics Corp. (NYSE: UMC) and an undisclosed strategic investor.
Eran is a veteran of the technology industry, with over 20 years of experience in various companies, both mature and startups, in which he held executive and senior level positions in corporate development, product strategy and marketing.
Eran brings with him proven experience in developing new businesses from scratch, with strong multi disciplinary technical background. Eran holds a B.Sc.EE degree from the Tel-Aviv University. Prior to founding Sensifree, Eran worked at Gilat Satellite Networks, Camero-Tech and Raysat Antenna Systems.
Ilan is an expert in microwaves, RF and chip design. With over 35 years of experience in the Israeli hi-tech industry and more than 20 patents filed by him, Ilan leads the technological innovation in Sensifree.
Ilan holds B.Sc. and M.Sc. degrees in electrical engineering, both from the Tel-Aviv University. Prior to founding Sensifree, Ilan worked at Gilat Satellite Networks, Intel and Raysat Antenna Systems.
Dr. Kamar is a board certified practicing general surgeon, with vast hands on experience in clinical and medical affairs, designing and overseeing multiple large scale clinical trials and FDA submissions.
Dr. Kamar also worked for Ornim Medical, Omrix Biopharmaceuticals, Johnson and Johnson and Teva Pharmaceuticals.
Asaf has over 16 years of business development, marketing and finance senior level roles in medical devices and biopharma companies.
His experience includes strategic planning and execution, product development and launch and crafting partnerships.
Asaf worked also for Johnson and Johnson, Omrix Biopharmaceuticals, Lumenis and PolyPid.
Dr. Benny Zeevi is an interventional pediatric cardiologist and leads the fund life science investments. He is a prominent figure and deeply involved in the Israeli life sciences and digital health industries. Dr. Zeevi is the chairman of the board of several companies and advisor to other companies. Dr. Zeevi holds an MD degree (Magna Cum Laude) from the Sackler School of Medicine, Tel Aviv University, Israel.
Eric leads TransLink’s activities supporting portfolio companies with their customers and partners, primarily in Greater China. He is interested in companies at the intersection of health and information technology, finance and technology, and consumer services. Eric is a founder of Eternal Capital and a private investor, board member, and advisor to public and private technology companies. He earned a B.A. in Economics from Harvard College.
Eran is a veteran of the technology industry, with over 20 years of experience in various companies, both mature and startups, in which he held executive and senior level positions in corporate development, product strategy and marketing. Eran brings with him proven experience in developing new businesses from scratch, with strong multi disciplinary technical background. Eran holds a B.Sc.EE degree from the Tel-Aviv University. Prior to founding Sensifree, Eran worked at Gilat Satellite Networks, Camero-Tech and Raysat Antenna Systems.
Ilan is an expert in microwaves, RF and chip design. With over 35 years of experience in the Israeli hi-tech industry and more than 20 patents filed by him, Ilan leads the technological innovation in Sensifree. Ilan holds B.Sc. and M.Sc. degrees in electrical engineering, both from the Tel-Aviv University. Prior to founding Sensifree, Ilan worked at Gilat Satellite Networks, Intel and Raysat Antenna Systems.
Dr. Sessler is the Michael Cudahy Professor and Chair of the Department of OUTCOMES RESEARCH at the Cleveland Clinic. He is also Director of the OUTCOMES RESEARCH CONSORTIUM: the Consortium is the world’s largest clinical anesthesia research group and publishes a full paper every 3 days. He is an editor for Anesthesiology and serves as a reviewer for more than 50 journals. His grants total $50 million. Dr. Sessler has published more than 700 full research papers which have been cited more than 30,000 times — making him the world’s most published anesthesiologist. His awards include a Fulbright Fellowship and the ASA Excellence in Research prize.
Dr. Wallace is a professor and vice-chair of anesthesiology and perioperative care at the University of California, San Francisco and Chief of the Anesthesia Service at the Veterans Affairs Medical Center in San Francisco. He completed a B.S. in engineering and applied science with a specialty in electrical engineering at Yale. He then completed an M.D. and Ph.D. at Johns Hopkins Medical School with his Ph.D. in biomedical engineering with research in systems physiology and autonomic control of the vasculature.